TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02993991

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The study has been terminated due to a change in internal prioritization and not due to any safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

2016201720182019Registered2016-12-01Planned start2017-10-10 (planned)Withdrawn (as of)2017-12-29

Vital statistics

Status
Withdrawn
Phase
Phase 1
Sponsor
University Health Network, Toronto
Sponsor type
University, hospital or other
Conditions
Squamous Cell Carcinoma, Head And Neck; Squamous Cell Carcinoma Mouth; Resectable Squamous Cell Carcinoma of Oral Cavity
Interventions
Mocetinostat; Durvalumab
Participants
0
Sites
1
Countries
Canada

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.